Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Preclinical studies performed with allosteric SHP2 inhibitors and combination treatments of SHP2 inhibitors with inhibitors of downstream regulators (such as MEK, ERK, and [PD-1] and anti-PD-L1 antibodies) demonstrate improved antitumor benefits.
Kanumuri et al. 2022 Expert Opinion on Therapeutic Targets 26(4): 319-332
While SHP2 inhibitors have exhibited promise in preclinical trials, numerous challenges remain in translation to the clinic, including [drug …